MA43402A - Composition pharmaceutique comprenant un inhibiteur puissant d'urat1 - Google Patents

Composition pharmaceutique comprenant un inhibiteur puissant d'urat1

Info

Publication number: MA43402A
Authority: MA; Morocco
Prior art keywords: powerful; pharmaceutical composition; composition including; urat1 inhibitor; urat1
Prior art date: 2015-12-08

Application number

MA043402A

Other languages

English (en)

Inventor

Gerry Burke

Johan Hjärtstam

Sha Liu

Wakeman Joanne Reiland

Colin Rowlings

Christer Tannergren

Corswant Christian Von

Original Assignee

Ardea Biosciences Inc

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-12-08

Filing date

2016-12-07

Publication date

2018-10-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57517882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA43402(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-12-07 Application filed by Ardea Biosciences Inc, Astrazeneca Ab filed Critical Ardea Biosciences Inc

2018-10-17 Publication of MA43402A publication Critical patent/MA43402A/fr

Links

ASUMVAPLXCRBMA-UHFFFAOYSA-N (3,5-dichloro-4-hydroxyphenyl)-(2,3-dihydro-1,4-benzoxazin-4-yl)methanone Chemical compound C1=C(Cl)C(O)=C(Cl)C=C1C(=O)N1C2=CC=CC=C2OCC1 ASUMVAPLXCRBMA-UHFFFAOYSA-N 0.000 title 1
229940083914 URAT1 inhibitor Drugs 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Pain & Pain Management (AREA)
Inorganic Chemistry (AREA)
Immunology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

MA043402A 2015-12-08 2016-12-07 Composition pharmaceutique comprenant un inhibiteur puissant d'urat1 MA43402A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201562264792P	2015-12-08	2015-12-08

Publications (1)

Publication Number	Publication Date
MA43402A true MA43402A (fr)	2018-10-17

Family

ID=57517882

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA043402A MA43402A (fr)	2015-12-08	2016-12-07	Composition pharmaceutique comprenant un inhibiteur puissant d'urat1

Country Status (20)

Country	Link
US (3)	US20180360761A1 (fr)
EP (1)	EP3386485A1 (fr)
JP (2)	JP6976946B2 (fr)
KR (1)	KR20180082613A (fr)
CN (1)	CN108289848A (fr)
AU (1)	AU2016368622B2 (fr)
BR (1)	BR112018011376A2 (fr)
CA (1)	CA3006167A1 (fr)
CL (1)	CL2018001510A1 (fr)
CO (1)	CO2018005842A2 (fr)
EA (1)	EA038828B9 (fr)
HK (2)	HK1253034A1 (fr)
IL (1)	IL259844B (fr)
MA (1)	MA43402A (fr)
MX (1)	MX394588B (fr)
PE (1)	PE20181521A1 (fr)
PH (1)	PH12018501236A1 (fr)
SG (1)	SG11201804100UA (fr)
WO (1)	WO2017097845A1 (fr)
ZA (1)	ZA201804519B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2704233T3 (es) *	2011-11-03	2019-03-15	Ardea Biosciences Inc	Compuesto de piridina 3,4-di-sustituido, procedimientos de uso y composiciones que comprenden el mismo
TWI780270B (zh) *	2017-11-28	2022-10-11	靜岡縣公立大學法人	固體分散體
WO2020070539A1 (fr) *	2018-10-01	2020-04-09	Astrazeneca Ab	Compositions pour réduire l'acide urique sérique
CN112057429B (zh) *	2019-06-11	2023-04-07	上海京新生物医药有限公司	雷西纳德控释药物组合物
PH12022550093A1 (en) *	2019-07-16	2022-11-21	Astrazeneca Ab	Dose dumping resistant pharmaceutical compositions comprising verinurad
UY39094A (es) *	2020-02-27	2021-07-30	Hk Inno N Corp	Composición farmacéutica que comprende compuesto derivado de bencimidazol
CN113368067A (zh) *	2020-07-23	2021-09-10	太阳升(亳州)生物医药科技有限公司	制备用于降低血液尿酸水平的口服药物片剂的方法
CN113368073A (zh) *	2020-07-23	2021-09-10	太阳升(亳州)生物医药科技有限公司	制备用于降低血液尿酸水平的药物制剂的方法
CN113368032A (zh) *	2020-07-23	2021-09-10	太阳升(亳州)生物医药科技有限公司	药物组合物、口服固体制剂及其制备方法和用途
WO2022162021A1 (fr)	2021-01-27	2022-08-04	Astrazeneca Ab	Compositions de vérinurad et procédés d'utilisation
AR126164A1 (es) *	2021-06-17	2023-09-27	Lg Chemical Ltd	Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico
KR20240055886A (ko) *	2021-09-17	2024-04-29	하이노바 파마슈티컬스 인코포레이티드	퀴놀린계 화합물의 서방성 정제 및 그 제조 방법
JP7515533B2 (ja) *	2022-04-28	2024-07-12	沢井製薬株式会社	デスロラタジン含有フィルムコーティング錠剤
JP2025535716A (ja) *	2022-10-04	2025-10-28	エングレイルセラピューティクス，インコーポレーテッド	Ｇａｂａａ受容体モジュレーターおよびその使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2010416B2 (de) *	1970-03-05	1979-03-29	Hoechst Ag, 6000 Frankfurt	Oral anwendbare Arzneiform mit Retardwirkung
JPH04234812A (ja) *	1990-03-16	1992-08-24	Yamanouchi Pharmaceut Co Ltd	持続性製剤用顆粒
JP2008530145A (ja) *	2005-02-15	2008-08-07	ワイス	経口投与可能なｃｃｉ−７７９製剤
DK1909766T3 (en) *	2005-07-28	2016-04-04	Shire Llc	PHARMACEUTICAL FORMULATIONS / FORMATIONS OF guanfacine SUITABLE FOR DAILY ADMINISTRATION IN SINGLE DOSE FORM
US20090104266A1 (en) *	2005-09-15	2009-04-23	Tobias Jung	3-(2-dimethylaminomethylcy clohexyl)phenol retard formulation
EP2560642A4 (fr) *	2010-03-30	2013-12-18	Ardea Biosciences Inc	Traitement de la goutte
ES2670700T3 (es) *	2010-06-15	2018-05-31	Ardea Biosciences, Inc.	Tratamiento de gota e hiperuricemia
AR081930A1 (es) *	2010-06-16	2012-10-31	Ardea Biosciences Inc	Compuestos de tioacetato
ES2704233T3 (es) *	2011-11-03	2019-03-15	Ardea Biosciences Inc	Compuesto de piridina 3,4-di-sustituido, procedimientos de uso y composiciones que comprenden el mismo

2016
- 2016-12-07 MA MA043402A patent/MA43402A/fr unknown
- 2016-12-07 PE PE2018001088A patent/PE20181521A1/es unknown
- 2016-12-07 SG SG11201804100UA patent/SG11201804100UA/en unknown
- 2016-12-07 KR KR1020187019068A patent/KR20180082613A/ko not_active Ceased
- 2016-12-07 JP JP2018529601A patent/JP6976946B2/ja not_active Expired - Fee Related
- 2016-12-07 CN CN201680071604.2A patent/CN108289848A/zh active Pending
- 2016-12-07 US US15/781,693 patent/US20180360761A1/en not_active Abandoned
- 2016-12-07 HK HK18112413.4A patent/HK1253034A1/zh unknown
- 2016-12-07 BR BR112018011376A patent/BR112018011376A2/pt not_active Application Discontinuation
- 2016-12-07 MX MX2018006903A patent/MX394588B/es unknown
- 2016-12-07 HK HK18115313.8A patent/HK1256256A1/zh unknown
- 2016-12-07 EA EA201891267A patent/EA038828B9/ru unknown
- 2016-12-07 EP EP16808626.2A patent/EP3386485A1/fr not_active Withdrawn
- 2016-12-07 WO PCT/EP2016/080111 patent/WO2017097845A1/fr not_active Ceased
- 2016-12-07 AU AU2016368622A patent/AU2016368622B2/en not_active Ceased
- 2016-12-07 CA CA3006167A patent/CA3006167A1/fr not_active Abandoned
2018
- 2018-06-06 CO CONC2018/0005842A patent/CO2018005842A2/es unknown
- 2018-06-06 IL IL259844A patent/IL259844B/en unknown
- 2018-06-06 CL CL2018001510A patent/CL2018001510A1/es unknown
- 2018-06-08 PH PH12018501236A patent/PH12018501236A1/en unknown
- 2018-07-06 ZA ZA2018/04519A patent/ZA201804519B/en unknown
2020
- 2020-08-31 US US17/007,041 patent/US20210113472A1/en not_active Abandoned
2021
- 2021-11-10 JP JP2021182955A patent/JP2022033758A/ja active Pending
2022
- 2022-06-23 US US17/808,390 patent/US20230011269A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN108289848A (zh)	2018-07-17
PH12018501236A1 (en)	2019-02-18
BR112018011376A2 (pt)	2018-12-04
MX394588B (es)	2025-03-24
US20230011269A1 (en)	2023-01-12
CA3006167A1 (fr)	2017-06-15
SG11201804100UA (en)	2018-06-28
IL259844A (en)	2018-07-31
IL259844B (en)	2022-04-01
CO2018005842A2 (es)	2018-07-10
JP2019501895A (ja)	2019-01-24
JP6976946B2 (ja)	2021-12-08
PE20181521A1 (es)	2018-09-24
EA038828B1 (ru)	2021-10-26
MX2018006903A (es)	2018-11-09
HK1256256A1 (zh)	2019-09-20
KR20180082613A (ko)	2018-07-18
ZA201804519B (en)	2022-04-28
EA038828B9 (ru)	2021-12-03
AU2016368622B2 (en)	2022-09-08
US20180360761A1 (en)	2018-12-20
EP3386485A1 (fr)	2018-10-17
AU2016368622A1 (en)	2018-06-07
US20210113472A1 (en)	2021-04-22
CL2018001510A1 (es)	2018-09-21
HK1253034A1 (zh)	2019-06-06
WO2017097845A1 (fr)	2017-06-15
JP2022033758A (ja)	2022-03-02
EA201891267A1 (ru)	2019-01-31

Publication	Publication Date	Title
NO2026004I1 (no)	2026-01-16	Sebetralstat or a pharmaceutically acceptable salt or solvate thereof
IL282304A (en)	2021-05-31	Topical pharmaceutical compositions
EP3493799A4 (fr)	2020-04-01	Composition pharmaceutique decannabis
MA44725A (fr)	2019-02-27	Formulations d'un inhibiteur de lsd1
EP3493798A4 (fr)	2020-05-06	Composition pharmaceutique decannabis
SI3529248T1 (sl)	2020-11-30	Farmacevtske spojine
DK3331864T3 (da)	2021-12-13	1,3,4-Oxadiazolderivat-forbindelser som histon-deacetylase-6-hæmmer, og den farmaceutiske sammensætning omfattende disse
DK3328843T3 (da)	2023-01-09	1,3,4-oxadiazolsulfonamidderivat-forbindelser som histon- deacetylase-6-inhibitor, og den farmaceutske sammensætning
DK3529240T3 (da)	2020-09-07	Farmaceutiske forbindelser
MA43705A (fr)	2018-11-28	Formulation pharmaceutique
MA43649A (fr)	2018-11-28	Formulations/compositions comprenant un inhibiteur de btk
MA43650A (fr)	2018-11-28	Formulations/compositions comprenant un inhibiteur de btk
DK3445351T3 (da)	2024-11-04	Acetyl-leucin eller et farmaceutisk acceptabelt salt deraf til forbedret mobilitet
HUE060732T2 (hu)	2023-04-28	Terápiás szer fibrózisra
EP3402470A4 (fr)	2019-11-13	Composition pharmaceutique stable
MA47516A (fr)	2021-03-31	Composition pharmaceutique
PL4003293T3 (pl)	2025-09-01	Rozwój farmaceutyczny
EP3383371A4 (fr)	2019-07-24	Formulation pharmaceutique
EP3459369A4 (fr)	2019-12-11	Composition pharmaceutique utilisant la souchelactobacillus
MA44079A (fr)	2021-04-21	Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine
BR112016030507A2 (pt)	2017-08-22	Compostos relacionados à vitamina d, composição farmacêutica, e kit
DK3728220T3 (da)	2022-02-07	Farmaceutiske forbindelser
EP3705122A4 (fr)	2021-12-22	Composition pharmaceutique à libération prolongée
EP3646863A4 (fr)	2021-03-24	Composition pharmaceutique
EP3646867A4 (fr)	2021-03-24	Composition pharmaceutique